Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Jun;39(6):671–675. doi: 10.1111/j.1365-2125.1995.tb05727.x

A double-blind, placebo controlled study of the effect of the specific histamine H1-receptor antagonist, terfenadine, in chronic severe asthma.

R Wood-Baker 1, R Smith 1, S T Holgate 1
PMCID: PMC1365080  PMID: 7654486

Abstract

1. The characteristic changes seen in asthma are widely regarded as being caused by local mediator release in the airways, with histamine the first putative mediator in asthma to be identified. 2. We performed a double-blind, randomised, placebo-controlled crossover trial of the effect of 4 weeks treatment with terfenadine 120 mg twice daily in chronic severe asthma. 3. Forty-two subjects (20 male and 22 female) completed the 10 week study. 4. Terfenadine had no significant treatment effect on the primary efficacy variables measured. Mean (95% CI) measurements for terfenadine vs placebo treatment periods were 1.5 vs 1.5 (-0.3, 0.3) l for FEV1, 259 vs 260 (-42, 40) l min-1 for morning PEF and 0.8 vs 0.8 (-0.3, 0.3) for global symptom scores. 5. Bronchodilator use and sleep disturbance, the secondary efficacy variables studied, showed an improvement during terfenadine treatment but this only reached statistical significance for the number of times subjects awoke from sleep (P = 0.04). 6. There was a similar frequency of minor adverse effects reported during placebo (13.6%) and terfenadine (16.7%) treatments. 7. Addition of the potent and specific histamine H1-receptor antagonist terfenadine to maintenance asthma treatment had no significant therapeutic benefit in this group of chronic severe asthmatics.

Full text

PDF
671

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Busse W. W., Swenson C. A. The relationship between plasma histamine concentrations and bronchial obstruction to antigen challenge in allergic rhinitis. J Allergy Clin Immunol. 1989 Nov;84(5 Pt 1):658–666. doi: 10.1016/0091-6749(89)90293-5. [DOI] [PubMed] [Google Scholar]
  2. Carr A. A., Meyer D. R. Synthesis of terfenadine. Arzneimittelforschung. 1982;32(9A):1157–1159. [PubMed] [Google Scholar]
  3. Curry J. J. THE ACTION OF HISTAMINE ON THE RESPIRATORY TRACT IN NORMAL AND ASTHMATIC SUBJECTS. J Clin Invest. 1946 Nov;25(6):785–791. doi: 10.1172/JCI101764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Curzen N., Rafferty P., Holgate S. T. Effects of a cyclo-oxygenase inhibitor, flurbiprofen, and an H1 histamine receptor antagonist, terfenadine, alone and in combination on allergen induced immediate bronchoconstriction in man. Thorax. 1987 Dec;42(12):946–952. doi: 10.1136/thx.42.12.946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dale H. H., Laidlaw P. P. The physiological action of beta-iminazolylethylamine. J Physiol. 1910 Dec 31;41(5):318–344. doi: 10.1113/jphysiol.1910.sp001406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dijkman J. H., Hekking P. R., Molkenboer J. F., Nierop G., Vanderschueren R., Bernheim J., Van Ganse E. H. Prophylactic treatment of grass pollen-induced asthma with cetirizine. Clin Exp Allergy. 1990 Sep;20(5):483–490. doi: 10.1111/j.1365-2222.1990.tb03140.x. [DOI] [PubMed] [Google Scholar]
  7. Djukanović R., Roche W. R., Wilson J. W., Beasley C. R., Twentyman O. P., Howarth R. H., Holgate S. T. Mucosal inflammation in asthma. Am Rev Respir Dis. 1990 Aug;142(2):434–457. doi: 10.1164/ajrccm/142.2.434. [DOI] [PubMed] [Google Scholar]
  8. Durham S. R., Lee T. H., Cromwell O., Shaw R. J., Merrett T. G., Merrett J., Cooper P., Kay A. B. Immunologic studies in allergen-induced late-phase asthmatic reactions. J Allergy Clin Immunol. 1984 Jul;74(1):49–60. doi: 10.1016/0091-6749(84)90086-1. [DOI] [PubMed] [Google Scholar]
  9. Eiser N. The effect of a beta 2-adrenergic agonist and a histamine H1-receptor antagonist on the late asthmatic response to inhaled antigen. Respir Med. 1991 Sep;85(5):393–399. doi: 10.1016/s0954-6111(06)80184-8. [DOI] [PubMed] [Google Scholar]
  10. Holgate S. T., Robinson C., Church M. K., Howarth P. H. The release and role of inflammatory mediators in asthma. Clin Immunol Rev. 1985;4(2):241–288. [PubMed] [Google Scholar]
  11. Nicholson A. N. Antihistaminic activity and central effects of terfenadine. A review of European studies. Arzneimittelforschung. 1982;32(9A):1191–1193. [PubMed] [Google Scholar]
  12. Patel K. R. Effect of terfenadine on methacholine-induced bronchoconstriction in asthma. J Allergy Clin Immunol. 1987 Feb;79(2):355–358. doi: 10.1016/0091-6749(87)90155-2. [DOI] [PubMed] [Google Scholar]
  13. Rafferty P., Holgate S. T. Terfenadine (Seldane) is a potent and selective histamine H1 receptor antagonist in asthmatic airways. Am Rev Respir Dis. 1987 Jan;135(1):181–184. doi: 10.1164/arrd.1987.135.1.181. [DOI] [PubMed] [Google Scholar]
  14. Rafferty P., Jackson L., Smith R., Holgate S. T. Terfenadine, a potent histamine H1-receptor antagonist in the treatment of grass pollen sensitive asthma. Br J Clin Pharmacol. 1990 Aug;30(2):229–235. doi: 10.1111/j.1365-2125.1990.tb03769.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rafferty P., Ng W. H., Phillips G., Clough J., Church M. K., Aurich R., Ollier S., Holgate S. T. The inhibitory actions of azelastine hydrochloride on the early and late bronchoconstrictor responses to inhaled allergen in atopic asthma. J Allergy Clin Immunol. 1989 Nov;84(5 Pt 1):649–657. doi: 10.1016/0091-6749(89)90292-3. [DOI] [PubMed] [Google Scholar]
  16. Roche W. R., Beasley R., Williams J. H., Holgate S. T. Subepithelial fibrosis in the bronchi of asthmatics. Lancet. 1989 Mar 11;1(8637):520–524. doi: 10.1016/s0140-6736(89)90067-6. [DOI] [PubMed] [Google Scholar]
  17. Taytard A., Beaumont D., Pujet J. C., Sapene M., Lewis P. J. Treatment of bronchial asthma with terfenadine; a randomized controlled trial. Br J Clin Pharmacol. 1987 Dec;24(6):743–746. doi: 10.1111/j.1365-2125.1987.tb03240.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Town G. I., Holgate S. T. Comparison of the effect of loratadine on the airway and skin responses to histamine, methacholine, and allergen in subjects with asthma. J Allergy Clin Immunol. 1990 Dec;86(6 Pt 1):886–893. doi: 10.1016/s0091-6749(05)80151-4. [DOI] [PubMed] [Google Scholar]
  19. Twentyman O. P., Ollier S., Holgate S. T. The effect of H1-receptor blockade on the development of early- and late-phase bronchoconstriction and increased bronchial responsiveness in allergen-induced asthma. J Allergy Clin Immunol. 1993 Jun;91(6):1169–1178. doi: 10.1016/0091-6749(93)90320-f. [DOI] [PubMed] [Google Scholar]
  20. Wardlaw A. J., Dunnette S., Gleich G. J., Collins J. V., Kay A. B. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. Am Rev Respir Dis. 1988 Jan;137(1):62–69. doi: 10.1164/ajrccm/137.1.62. [DOI] [PubMed] [Google Scholar]
  21. Weiner M. Sedation and antihistaminics. Arzneimittelforschung. 1982;32(9A):1193–1195. [PubMed] [Google Scholar]
  22. Wood-Baker R., Holgate S. T. The comparative actions and adverse effect profile of single doses of H1-receptor antihistamines in the airways and skin of subjects with asthma. J Allergy Clin Immunol. 1993 May;91(5):1005–1014. doi: 10.1016/0091-6749(93)90213-y. [DOI] [PubMed] [Google Scholar]
  23. Woodward J. K., Munro N. L. Terfenadine, the first non-sedating antihistamine. Arzneimittelforschung. 1982;32(9A):1154–1156. [PubMed] [Google Scholar]
  24. Woosley R. L., Chen Y., Freiman J. P., Gillis R. A. Mechanism of the cardiotoxic actions of terfenadine. JAMA. 1993 Mar 24;269(12):1532–1536. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES